规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
靶点 |
DPP-2; cytosol alanyl aminopeptidase
|
---|---|
体外研究 (In Vitro) |
嘌呤霉素氨基核苷 (PAN) 会导致 MC 凋亡,并伴有细胞活力下降和炎症反应增加。 ERRα过表达加剧了经PAN处理的MCs中由PAN引起的细胞凋亡。 [1]
|
体内研究 (In Vivo) |
根据体外研究,用 PAN 治疗的大鼠肾皮质显示 ERRα 表达增加,这与细胞凋亡反应增强一致。 [1]
|
细胞实验 |
在 96 孔板上,细胞以每孔 5,000 个细胞的密度接种在含有 10% FBS 的 MEM 中。孵育约 48 小时(约 40-50% 汇合)后,将细胞转移至含有不同浓度的嘌呤霉素氨基核苷 (NSC 3056) 的新生长培养基中。为了进行保护实验,将细胞培养在含有 250 μM 嘌呤霉素氨基核苷 (NSC 3056) 或 2 μM Decynium-22(一种 PMAT 抑制剂)的培养基中。在 95% O2 的培养箱中于 37°C 培养 72 小时后,清洗细胞和培养板。 IC50 值是通过将细胞生长数据非线性回归到以下模型(WinNonLin 版本 3.2)获得的: S 是光密度与未处理对照细胞的细胞存活率的百分比,表示为 S max - [Smax - S0] × [Cγ/(Cγ + IC50γ)],其中S0是高药物浓度下的最低残留细胞存活率,C是嘌呤霉素氨基核苷的浓度,γ是希尔系数,IC< sub>50是导致半最大细胞存活的嘌呤霉素氨基核苷的浓度。在每个实验中,进行四次单独的实验,并做出五到六次测定。
|
动物实验 |
Male F344 rats at 11 weeks of age are purchased from JaPuromycin aminonucleoside SLC. In this study, a Puromycin aminonucleoside nephrosis model and normal rats are used. Rats are given a single intravenous injection of puromycin aminonucleoside (NSC 3056) at a dose of 8 mg/100 g body weight in saline to cause puromycin aminonucleoside nephrosis. The volume of saline given to control animals is the same. Days 4 and 7 following the Puromycin aminonucleoside injection are studied in nephrotic rats (n=6 per group).
|
参考文献 |
分子式 |
C12H18N6O3
|
---|---|
分子量 |
294.309721469879
|
精确质量 |
294.14
|
元素分析 |
C, 48.97; H, 6.16; N, 28.56; O, 16.31
|
CAS号 |
58-60-6
|
相关CAS号 |
58-60-6 (Puromycin Aminonucleoside); 58-58-2 (Puromycin 2HCl); 53-79-2 (Puromycin free base)
|
外观&性状 |
Solid powder
|
SMILES |
CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O
|
InChi Key |
RYSMHWILUNYBFW-GRIPGOBMSA-N
|
InChi Code |
InChI=1S/C12H18N6O3/c1-17(2)10-8-11(15-4-14-10)18(5-16-8)12-9(20)7(13)6(3-19)21-12/h4-7,9,12,19-20H,3,13H2,1-2H3/t6-,7-,9-,12-/m1/s1
|
化学名 |
(2R,3R,4S,5S)-4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol
|
别名 |
NSC3056; NSC-3056; Puromycin Aminonucleoside; ARDMA; NSC 3056; SAN; Stylomycin aminonucleoside
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: 25~59 mg/mL (84.9~200.5 mM)
Water: ~30 mg/mL (~101.9 mM) |
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.49 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.49 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 6: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 7: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 8: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 9: ≥ 2.08 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. Solubility in Formulation 10: 12.5 mg/mL (42.47 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3978 mL | 16.9889 mL | 33.9778 mL | |
5 mM | 0.6796 mL | 3.3978 mL | 6.7956 mL | |
10 mM | 0.3398 mL | 1.6989 mL | 3.3978 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Puromycin aminonucleoside (PAN) treatment induced mesangial cell inflammation and decreased cell viability. Am J Physiol Renal Physiol . 2019 May 1;316(5):F906-F913. td> |
Puromycin aminonucleoside (PAN) treatment induced mesangial cell apoptosis. Am J Physiol Renal Physiol . 2019 May 1;316(5):F906-F913. td> |
Puromycin aminonucleoside (PAN) treatment induced estrogen-related receptor-α (ERRα) expression in mesangial cells. Am J Physiol Renal Physiol . 2019 May 1;316(5):F906-F913. td> |
Estrogen-related receptor-α (ERRα) overexpression accelerated puromycin aminonucleoside (PAN)-induced mesangial cell apoptosis. Am J Physiol Renal Physiol . 2019 May 1;316(5):F906-F913. td> |